Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 Compared to MabThera (Rituximab by Hoffman-La Roche) in Patients With Diffuse Large B-cell Lymphoma
Latest Information Update: 27 Oct 2023
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Pharmacokinetics
- Acronyms MADILYM
- Sponsors Mabion
- 13 May 2020 Status changed from recruiting to completed.
- 01 Jun 2016 Status changed from not yet recruiting to recruiting.
- 03 Dec 2015 New trial record